Clinical trials: COVID-19
COVID-19
DAS181 for STOP COVID-19
It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of…
- Trial name
- NCT04354389
- Testing
- DAS181
- Where
- 2 sites in Italy
- Sponsor
- Ansun Biopharma, Inc.
Healthy
A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
The purpose of this study is to learn how Itraconazole affects the blood level of PF-07817883 in Healthy Adults. This study is seeking participants who are: male and female aged 18 to 65 years old, overtly healthy.
- Trial name
- NCT05822440
- Testing
- PF-07817883, Itraconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization…
- Trial name
- NCT05541289
- Testing
- BBV152
- Where
- United States
- Sponsor
- Ocugen
Covid19
Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization
The purpose of this research is to remotely monitor individuals who have tested positive for COVID-19 to learn more about progression and recovery from the disease.
- Trial name
- RiskSEARCH (NCT04709068)
- Testing
- Current Health
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Current Health
COVID-19
THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines
This is a phase 1/2 open-label study assessing the safety, reactogenicity, and immunogenicity of saRNA COVID-19 boost vaccines in participants that have been previously vaccinated against or previously infected with COVID-19.
- Trial name
- NCT05370040
- Testing
- AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine
- Where
- South Africa
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
COVID-19
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
The purpose of this study is to assess the immunogenicity and safety of SCB-2023 trivalent vaccine compared to the prototype SCB-2019 monovalent vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19…
- Trial name
- NCT05926440
- Testing
- SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
- Where
- 3 sites in Philippines
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19, ARDS, Human
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
This study consists of two parts. Part A (Phase I): A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001 Part B (Phase 2): A Phase IIa…
- Conditions
- COVID-19, ARDS, Human, Stem Cells, Regeneration
- Trial name
- NCT04646603
- Testing
- MRG-001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- MedRegen LLC
Coronavirus Disease 2019
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by…
- Trial name
- NCT04343651
- Testing
- Leronlimab (700mg)
- Where
- 12 sites in United States
- Volunteers
- 86 people
- Sponsor
- CytoDyn, Inc.
COVID-19
Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination
This study is Post Authorization Safety Study (PASS) Phase IV of Booster IndoVac COVID-19 Vaccination
- Trial name
- NCT06690502
- Where
- 28 sites in Indonesia
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Covid19, Respiratory Disease
Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
This is a two-arm, randomized, open label, two-center, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019…
- Conditions
- Covid19, Respiratory Disease, Immune System, Immunomodulator
- Trial name
- NCT04701502
- Testing
- Viusid, Asbrip, Standard Care
- Where
- 2 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
SARS-COV2 Infection
Validation of HyperDetector for SARS-CoV-2
To evaluate the HyperDetector as a method to rapidly screen SARS-CoV-2 To determine the sensitivity and specificity of the screening assay performed on oral swab and saliva specimens, compared to a validated RT-PCR COVID-19…
- Trial name
- NCT05124496
- Testing
- Screening Device
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- HyperSpectral APD
Immunogenicity, Safety
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose.
- Conditions
- Immunogenicity, Safety, Efficacy
- Trial name
- NCT05686161
- Testing
- SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2.
- Where
- Laos
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
Covid-19
Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers
The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study
- Trial name
- NCT04366180
- Testing
- Probiotic, Control
- Where
- Spain
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac）manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04894227
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell）
- Where
- China
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2 Infection
A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
This study is a combined Phase 1 and Phase 2 study with IV infusion of NGM621 to evaluate the safety, tolerability, and PK in healthy volunteers (Part 1), and safety, tolerability, PK and efficacy in subjects with confirmed…
- Trial name
- NCT04582318
- Testing
- NGM621
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019…
- Trial name
- COMET-PACE (NCT05124210)
- Testing
- Sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
COVID-19, Influenza
Performance Evaluation of the Lucira COVID-19 & Flu Test
The Lucira COVID-19\& Flu Test is a single use (disposable) RT-LAMP test kit intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral RNA in anterior…
- Trial name
- NCT06141824
- Testing
- Lucira COVID-19 & Flu Test
- Where
- 7 sites in United States
- Volunteers
- 1,361 people
- Sponsor
- Lucira Health Inc
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.